GLP1R and type 2 diabetes mellitus: Thus GLP-1 receptor agonists (e.g., exendin-4 and liraglutide) that are more stable and resistant to proteases are used as a therapeutic option in the treatment of type 2 diabetes, based on their glucoregulatory and anorectic actions in mice and humans [91,128,129].